Tardbp Mutations In Amyotrophic Lateral Sclerosis plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Mutations in the TARDBP gene, which encodes the TDP-43 protein, are a well-established cause of familial amyotrophic lateral sclerosis (ALS). TDP-43 is the major pathological protein in virtually all ALS cases (except those caused by SOD1 or FUS mutations), making understanding TARDBP mutations crucial for comprehending ALS pathogenesis.
The TARDBP gene is located on chromosome 1p36.22 and encodes:
- Protein: TAR DNA-binding protein 43 (TDP-43)
- Function: RNA-binding protein involved in RNA splicing, stability, and transport
- Molecular weight: ~414 amino acids
- Key domains: N-terminal domain, RNA recognition motif (RRM), C-terminal glycine-rich domain
Over 50 pathogenic TARDBP mutations have been identified:
| Mutation |
Location |
Frequency |
Phenotype |
| A382T |
C-terminal |
Most common |
Classic ALS |
| M337V |
C-terminal |
Common |
ALS/FTD |
| G298S |
C-terminal |
Rare |
Early onset |
| Q331K |
C-terminal |
Rare |
Variable |
| N345K |
C-terminal |
Rare |
ALS |
| D169G |
RRM |
Rare |
FTD |
- Majority: Located in C-terminal glycine-rich region
- Effect: Protein mislocalization and aggregation
- Inheritance: Autosomal dominant
TDP-43 is a nuclear RNA-binding protein that:
- Regulates alternative splicing
- Stabilizes mRNA transcripts
- Participates in RNA processing
- Modulates gene expression
- Mutant TDP-43 accumulates in cytoplasm
- Loss of nuclear function
- Formation of stress granules
- Progression to inclusions
- C-terminal mutations promote aggregation
- Insoluble inclusions in neurons
- Sequestration of normal TDP-43
- Disruption of RNA metabolism
- Aberrant splicing patterns
- Altered mRNA stability
- Disrupted transport to synapses
- Impaired stress response
- Reduced nuclear TDP-43 activity
- Dysregulation of critical neuronal transcripts
- Nuclear depletion in disease
TDP-43 inclusions are the hallmark of ALS:
- Location: Motor neurons, surrounding glia
- Composition: Phosphorylated, ubiquitinated TDP-43
- Types: Skeletal, compact, Lewy body-like
- Age of onset: 45-65 years (variable)
- Site of onset: Limb (70-80%) or bulbar (20-30%)
- Progression: Variable, typically 2-5 years
- Survival: Similar to sporadic ALS
| Mutation |
Onset |
Progression |
Notes |
| A382T |
~50 years |
Variable |
Most common, Italy cluster |
| M337V |
~52 years |
Variable |
ALS/FTD possible |
| G298S |
~45 years |
Variable |
Early onset |
- Classic ALS phenotype: Mixed upper/lower motor neuron
- Cognitive involvement: 10-15% develop FTD
- Extrapyramidal features: Possible in some families
- Respiratory involvement: Common progression
- Method: PCR and Sanger sequencing
- Indication: ALS with family history, early onset
- Interpretation: Pathogenic variants confirm genetic etiology
| Biomarker |
Relevance |
| Total TDP-43 in CSF |
May be elevated |
| Neurofilament light chain (NfL) |
Disease progression marker |
| Phosphorylated TDP-43 |
Diagnostic in research |
- ASOs targeting mutant TARDBP mRNA
- Challenge: Balancing mutant reduction with normal function
- Preclinical development ongoing
- Small molecules preventing aggregation
- Enhancement of protein clearance
- Correcting splicing dysregulation
- Stabilizing mRNA transcripts
- Gene therapy: Viral delivery of ASOs
- Protein homeostasis: Enhancing autophagy/ubiquitin system
- Neuroprotection: Addressing oxidative stress
- Cell-based therapies: Stem cell approaches
- TARDBP transgenic mice: Show TDP-43 pathology
- Mutant knock-in mice: Model human disease
- iPSC-derived neurons: Patient-specific models
- Mutant TARDBP sufficient for neurodegeneration
- TDP-43 pathology spreads in CNS
- Non-neuronal cells contribute
- Therapeutic window exists
TDP-43 pathology is present in:
- SOD1-ALS: Rare, usually absent
- FUS-ALS: TDP-43 negative inclusions
- C9orf72-ALS: TDP-43 positive
- Sporadic ALS: Universal TDP-43 pathology
Tardbp Mutations In Amyotrophic Lateral Sclerosis plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Tardbp Mutations In Amyotrophic Lateral Sclerosis has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.